Device Trial Radar · NCT03704168
Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders
Last checked: Nov 19, 2026Latest source record: Nov 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 1, 2019
Primary completion
Apr 30, 2021
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- Dean NakamotoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 12, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate safety of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations. Secondary Objective: To evaluate efficacy of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations. Duration: Estimation for Recruitment: 12 months Estimation for Procedure/Trial: 1 visit with an overnight observation Estimation for Subject Follow Up: 7 days, 14 days, 28 days, 90 days, and 180 days, post ablation, with ultrasound of the bilateral submandibular glands at 28 days and 180 days post ablation Total Expected Duration for Clinical Trial: 2 years
Conditions
- Sialorrhea
- Neurologic Disorder
Interventions
CRYOABLATIONDevice
The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate safety of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations.Time frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.